Complementary Route Networks, Diversified Fleet, and Third-Party Travel Business Expand Choice, and Service for Passengers, Allowing Them to Reach More U.S. and International Vacation Destinations ...
One-year follow-up data from Phase 2 trial of once-weekly canvuparatide, a potential best-in-class therapy for ...
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva’s anti-IL-15 candidate, TEV-‘408 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback